Depression is the single largest contributor to global disability, affecting approximately 322 million people worldwide.1 In addition to its high prevalence, depression can impair functionality, impact the quality of life, and lead to suicide in more severe cases. Conventional antidepressant treatments have a delayed onset of action, taking weeks to exert their effects…


Previous articleMindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates
Next articleTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida